논문 목록
3건-
BRUIN 313 and 314 Trials Open the Door for Noncovalent Bruton Tyrosine Kinase Inhibition as Initial Therapy for Chronic Lymphocytic Leukemia.
In the articles that accompany this editorial, continuous treatment with the non-covalent Bruton Tyrosine Kinase inhibitor (BTKi) pirtobrutinib for chronic lymphocytic leukemia (CLL) is compared in phase 3, randomized trials to either a cou…
-
First-line treatment for CLL in the era of targeted therapy.
In the decade since FDA approval of the first-generation Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, the treatment landscape for chronic lymphocytic leukemia (CLL) has transformed. Targeted agents, as monotherapy or in combination r…
-
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 study.
[BACKGROUND] Despite recent chronic lymphocytic leukemia (CLL) treatment advances, resistance and intolerance are challenges. Lisaftoclax is a selective, small-molecule oral BCL-2 inhibitor. [METHODS] Lisaftoclax was administered with init…